Introduction to EPC and the Role of AMPA Receptors

Epilepsia partialis continua (EPC) represents a rare and uniquely challenging subtype of focal motor status epilepticus. It is characterized by persistent, rhythmic clonic movements of a specific body part, typically lasting for hours, days, or even weeks. Clinically, EPC remains notoriously difficult to treat, often displaying profound resistance to conventional antiseizure medications (ASMs). For neurologists and critical care specialists in India, managing these patients requires a balance between aggressive seizure control and the prevention of drug-induced toxicity. Currently, there are no universally accepted guidelines for the pharmacological management of EPC, leading to significant variability in clinical practice. This therapeutic gap has spurred interest in newer agents with novel mechanisms of action, such as perampanel. Perampanel, a non-competitive antagonist of the AMPA receptor, has emerged as a promising candidate for treating refractory status epilepticus. Its unique ability to block excitatory glutamatergic transmission offers a distinct advantage over GABAergic drugs, which often lose efficacy as status epilepticus progresses. Recent real-world data provide evidence for the effectiveness of perampanel for EPC treatment.

The Pathophysiological Basis for Perampanel for EPC Treatment

The pathophysiology of prolonged status epilepticus involves a shift in the balance between inhibitory and excitatory neurotransmission. Early in the course of seizures, GABA receptors are internalized, leading to a diminished response to benzodiazepines and other traditional medications. Conversely, there is an upregulation and increased expression of AMPA receptors at the synaptic level. This "glutamate storm" sustains the seizure activity and contributes to the progressive nature of the condition. Specifically, perampanel targets this mechanism by binding to the non-competitive site of the AMPA receptor. Consequently, it effectively inhibits the flow of sodium and calcium ions into the postsynaptic neuron, thereby reducing neuronal hyperexcitability. Unlike competitive antagonists, perampanel does not compete with glutamate, making it highly effective even when synaptic glutamate concentrations are significantly elevated. Furthermore, its long half-life and once-daily dosing potential make it an attractive option for both acute stabilization and long-term maintenance. In the context of EPC, where focal motor activity can be relentless, the rapid blockade of excitatory pathways is crucial for clinical success.

Analysis of Recent Case Series Data

In a recently published retrospective analysis by Lahsaee et al., researchers evaluated the efficacy of perampanel in a group of eight patients suffering from epilepsia partialis continua. The study, conducted between January 2024 and March 2025, focused on patients who had failed initial lines of therapy and required adjunctive treatment. The etiology of EPC in these patients included intracranial hemorrhage and glioblastoma, reflecting the typical high-acuity profile seen in tertiary care hospitals. A significant finding of this series was that perampanel for EPC treatment resulted in seizure termination in 100% of the subjects. All eight patients achieved seizure freedom within a 72-hour window after the drug was introduced as the last added antiseizure medication. The time to clinical response varied, with some patients responding in less than 24 hours, while others required up to 72 hours for complete cessation of focal motor activity. This high success rate is particularly noteworthy given the historically drug-resistant nature of EPC and suggests that the drug is a robust anti-epileptic agent.

Loading Dose Protocols and Oral Administration

One of the critical aspects of using perampanel for EPC treatment is the determination of an effective loading dose. In the analyzed series, loading doses ranged from 6 mg to 20 mg, administered orally. While the standard maintenance dose for epilepsy typically ranges from 4 mg to 12 mg, higher loading doses are often necessary in the acute setting to achieve therapeutic plasma concentrations rapidly. Interestingly, the study found that oral doses up to 16 mg were well-tolerated, particularly in conscious patients. In India, where intravenous formulations of newer ASMs may not always be accessible in every center, the efficacy of the oral route is a significant practical advantage. The drug can be administered via a nasogastric tube in patients who are unable to swallow, ensuring that treatment is not delayed. Furthermore, researchers observed that higher oral loading doses were associated with a favorable clinical response without causing excessive respiratory depression. However, clinicians must remain vigilant regarding pharmacokinetic interactions, especially when using perampanel alongside enzyme-inducing drugs like phenytoin, which can reduce its levels.

Safety Profile and Side Effect Management

While the efficacy of perampanel for EPC treatment is compelling, its safety profile must be carefully considered. The most common side effects observed in clinical practice include sedation, delirium, agitation, and nausea. These adverse events are consistent with the known pharmacodynamic profile of AMPA receptor antagonists. Sedation and delirium can be particularly challenging in the intensive care unit (ICU) setting, as they may complicate the neurological assessment of the patient. Moreover, agitation is a well-documented concern for perampanel and requires close monitoring by nursing staff. Despite these risks, the study indicated that the drug was generally well-tolerated in conscious patients when used as an early adjunct. To mitigate behavioral side effects, some experts recommend bedtime administration, although in the acute setting of EPC, the priority remains rapid seizure control. Clinicians should also be aware of the potential for dizziness and ataxia, which can increase the risk of falls in ambulatory patients. Overall, the benefit-risk ratio in focal motor status epilepticus seems to favor perampanel use when managed properly.

Clinical Implications for Status Epilepticus Hierarchy

The findings from recent real-world data suggest that perampanel should be considered an effective early adjunct therapy for patients with epilepsia partialis continua. In the hierarchy of status epilepticus management, it serves as a valuable bridge between second-line agents and more invasive third-line anesthetic agents. For practitioners in India, the availability of a potent oral medication that can terminate refractory focal seizures is a welcome development. The ability of perampanel to target the underlying synaptic changes that occur during prolonged seizures makes it a mechanistically sound choice. Furthermore, its high success rate in terminating EPC across various etiologies provides a level of reassurance for clinicians facing this difficult condition. As we move towards more personalized approaches in epilepsy care, identifying the specific subtypes of status epilepticus that respond best to AMPA receptor blockade will be a priority for future research. Nevertheless, the current evidence strongly supports the role of perampanel as a vital component of the modern therapeutic strategy for managing epilepsia partialis continua and other refractory focal motor seizures.

Frequently Asked Questions

Why is perampanel specifically useful for treating Epilepsia Partialis Continua compared to other medications?

Perampanel is uniquely effective because it acts as a non-competitive AMPA receptor antagonist. During prolonged seizures like EPC, the brain's GABA receptors often become internalized and less effective, leading to benzodiazepine resistance. Simultaneously, AMPA receptors are upregulated, fueling continued seizure activity. By blocking these excitatory pathways directly, perampanel for EPC treatment can terminate seizures that have become resistant to traditional GABAergic drugs, providing a critical alternative for managing drug-resistant focal motor status epilepticus.

What are the recommended loading doses for perampanel when managing acute EPC cases?

Current clinical data, including recent case series, suggest an oral loading dose ranging from 6 mg to 20 mg for treating EPC. While the standard daily maintenance dose is usually lower, higher initial doses are necessary to rapidly reach therapeutic plasma levels in acute status epilepticus settings. Some clinical protocols have utilized even higher doses in super-refractory cases. However, clinicians must balance the need for rapid control with the patient’s consciousness level and potential for sedation.

What are the primary safety concerns when using perampanel as an adjunct therapy in conscious patients?

The most frequent safety concerns include neuropsychiatric symptoms such as sedation, delirium, and agitation. In conscious patients, perampanel for EPC treatment may also cause dizziness, ataxia, and nausea. It is particularly important to monitor for behavioral changes or aggression, which are known risks associated with this medication. Because of its long half-life, these side effects may persist for several days. Close clinical monitoring and careful patient selection are essential in the acute setting.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Clinicians should use their professional judgment and consider individual patient factors when making treatment decisions. Refer to the latest local and national guidelines for clinical practice.

References

Lahsaee S et al. Exploring the efficacy and safety of perampanel in epilepsia partialis continua: A case series. Epileptic Disord. 2026 Jul 03. doi: 10.1002/epd2.70318. PMID: 42397690.

Brigo F, et al. Perampanel in the treatment of status epilepticus: A systematic review of the literature. Epilepsy Behav. 2021;116:107758. doi: 10.1016/j.yebeh.2020.107758.

Rossetti AO, et al. Management of status epilepticus in adults. UpToDate. 2024. [Accessed June 2026].